免疫反应中的胰蛋白酶原联合胰腺炎相关蛋白测定作为筛查新生儿囊性纤维化的一种方法  

Combining immunoreactive trypsinogen and pancreatitis-associated protein assays, a method of newborn screening for cystic fibrosis that avoids DNA analysis

作　　者：Sarles J. Berthézène P. Le Louarn C. 郭战宏 

机构地区：[1]Service de Pédiatrie Multidisciplinaire, Hpital d' Enfants de la Timone, F-13385 Marseille Cedex 05, France Dr.

出　　处：《世界核心医学期刊文摘（儿科学分册）》2006年第2期24-24,共1页

摘　　要：Objectives: To evaluate the performance of a strategy in which, after immunoreactive trypsinogen (IRT) determination, genetic analysis is replaced by a biological test, the pancreatitis-associated protein (PAP) enzyme-linked immunosorbent assay (ELISA). Study design: The French newborn screening program includes cystic fibrosis (CF) screening by the IRT/CFTR mutation strategy. PAP was assayed on screening cards, in parallel with IRT, in all newborns from 5 French regions (n = 204,749). Analysis of PAP values in CF and non-CF newborns with elevated IRT allowed direct comparison between the current strategy and the proposed IRT/PAP strategy. Results: A protocol in which newborns with IRT >50 ng/mL and PAP >1.8 ng/mL and those with IRT >100 ng/mL and PAP >1.0 ng/mL are directly recalled for sweat testing would have the same performance as the IRT/CFTR mutation strategy. Conclusions: The IRT/PAP strategy is an alternative for CF newborn screening, which avoids the drawbacks of genetic analysis and is cheaper and easier to implement than the current IRT/CFTR mutation strategy.Objectives： To evaluate the performance of a strategy in which, after immunoreactive trypsinogen （IRT） determination, genetic analysis is replaced by a biological test, the pancreatitis-associated protein （PAP） enzyme-linked immunosorbent assay （ELISA） . Study design： The French newborn screening program includes cystic fibrosis （CF） screening by the IRT/CFI＇R mutation strategy. PAP was assayed on screening cards, in parallel with IRT, in all newborns from 5 French regions （n = 204, 749）. Analysis of PAP values in CF and non-CF newborns with elevated IRT allowed direct comparison between the current strategy and the proposed IRT/PAP strategy. Results： A protocol in which newborns with IRT 〉 50 ng/mL and PAP 〉 1.8 ng/mL and those with IRT 〉 100 ng/mL and PAP 〉 1.0 ng/mL are directly recalled for sweat testing would have the same performance as the IRT/CFTR mutation strategy.

关 键 词：胰腺炎相关蛋白 新生儿筛查 囊性纤维化 胰蛋白酶原 蛋白测定 筛查计划 免疫反应 酶联免疫吸附实验 CFTR 联合 

分 类 号：R576[医药卫生—消化系统] R722.11[医药卫生—内科学]